PANCE Blueprint Endocrinology (6%)

Pituitary Disorders (PEARLS)

PANCE and PANRE Endocrine System Content Blueprint pituitary disorders


Acromegaly/gigantism

Patient with acromegaly will present as → a 50-year-old man who comes to the clinic expressing concerns about noticeable changes in his appearance over the last five years. He mentions that he’s had to buy larger shoes and gloves due to swelling of his hands and feet. He also reports increased snoring and interrupted sleep, frequent headaches, and joint pain. On examination, he displays prominent brow ridges, an enlarged nose, thickened lips, and spaces between his teeth. Additionally, he has a deepened, husky voice and exhibits skin tags. An X-ray of the hand reveals enlarged finger bones. Magnetic resonance imaging (MRI) of the brain indicates an enlarged pituitary gland. Lab tests show elevated levels of insulin-like growth factor-1 (IGF-1).

Patient with gigantism will present as → a 13-year-old boy brought in by his parents due to rapid growth over the past two years. They mention he’s much taller than his peers, and his shoe size has increased significantly. The parents also express concerns about his persistent headaches and excessive sweating. On examination, the boy displays elongated arms and legs, a protruding jaw, and enlarged hands and feet. His growth charts show he’s above the 99th percentile for height for his age group. A visual field test reveals peripheral vision loss. Laboratory tests indicate elevated levels of growth hormone (GH) and insulin-like growth factor-1 (IGF-1). An MRI of the brain reveals a pituitary adenoma.

Etiology: Gigantism and acromegaly are usually caused by a pituitary adenoma that secretes excessive amounts of Growth Hormone; rarely, they are caused by non-pituitary tumors that secrete GHRH

  • Gigantism occurs if growth hormone (GH) hypersecretion begins in childhood, before the closure of the epiphyses
  • Acromegaly involves growth hormone GH hypersecretion beginning in adulthood; a variety of bony and soft tissue abnormalities develop (remember, Acromegaly has an "A" for adulthood!)

Presentation:

  • Large hands, feet, nose, lips, ears, jaw, tongue
  • Presents as gigantism (excessive height) if it occurs before epiphyseal closure

DX:

  • IGF-1 (somatomedin C) — best initial screening test; elevated in virtually all active acromegaly; single measurement; age- and sex-adjusted; unlike GH (which is pulsatile), IGF-1 provides a stable integrated measure of GH activity
  • Oral glucose tolerance test (OGTT) with GH measurement — gold standard confirmatory test: give 75g glucose; measure GH at 0, 30, 60, 90, 120 minutes; normal = GH suppressed to <1 ng/mL; acromegaly = GH fails to suppress (or paradoxically rises)
  • MRI pituitary with gadolinium: identify adenoma size and extent
  • Visual field testing (Humphrey): assess for bitemporal hemianopsia
  • Colonoscopy: increased colon polyp/cancer risk
  • Echocardiogram: assess cardiomegaly/LVH

TX:Transsphenoidal surgery (TSS) — first-line for most patients; cure rate ~80–90% for microadenomas, ~50–60% for macroadenomas; first-line when tumor resectable

Endocrine growth regulation - GHRH and Somatostatin axis

Gigantism and acromegaly are usually caused by a pituitary adenoma that secretes excessive amounts of growth hormone. Image by Mikael Häggström, Public domain, via Wikimedia Commons 

PEARLS:

Acromegaly: IGF-1 is the best screening test; OGTT with GH non-suppression is the gold standard confirmation

GH-secreting pituitary adenoma is the cause in 95%+

Transsphenoidal surgery is first-line. Somatostatin analogs (octreotide/lanreotide) are the primary medical therapy — remember they cause gallstones.

Pegvisomant is the most effective medical option for IGF-1 normalization

Acromegaly increases colon polyp and cancer risk — screen with colonoscopy

Diabetes insipidus (ReelDx)

ReelDx Virtual Rounds (Diabetes insipidus)
Patient will present as → a 25-year-old male complaining of an unabated thirst that began three weeks ago. He is constantly drinking and goes to the bathroom around five times a night. He has lost five pounds over the last few weeks. The patient is on lithium for bipolar disorder. His BP is 115/70. The patient’s labs are significant for serum Na of 145 mEq/L (normal: 135-145). Urine osmolality is 185 mOsm/kg, and urine specific gravity is 1.004 (normal: 1.012 to 1.030).

Diabetes insipidus (DI) is caused by a deficiency of or resistance to vasopressin (ADH), which decreases the kidneys' ability to reabsorb water, resulting in massive polyuria

  1. Central diabetes insipidus - Deficiency of ADH from posterior pituitary/hypothalamus
    • No ADH production most common type: idiopathic, autoimmune destruction of the posterior pituitary from head trauma, brain tumor, infection, or sarcoidosis
  2. Nephrogenic diabetes insipidus - Lack of reaction to ADH
    • Partial or complete insensitivity to ADH: caused by drugs (Lithium, Amphoterrible), hypercalcemia, and hypokalemia affect the kidney's ability to concentrate urine, acute tubular necrosis

Diagnosis:

  • 24 hr urine –specific gravity 1.006
  • Vasopressin challenge test (central DI)

Serum osmolality (concentration) is high (unable to stop the secretion of water into the kidneys so blood becomes more concentrated), and urine osmolality is low because it is so dilute

The water deprivation test is the simplest and most reliable method for diagnosing central diabetes insipidus but should be done only while the patient is under constant supervision. Serious dehydration may result

  • The normal response is progressive urine concentration
  • Diabetes insipidus results in the continued production of dilute urine despite water deprivation

Treatment:

  • Central – desmopressin
  • Nephrogenic— indomethacin +/- HCTZ, desmopressin

PEARLS:

Central DI: low ADH → give DDAVP (responds). Nephrogenic DI: normal/high ADH, resistant kidneys → give thiazide diuretic (paradoxical).

The DDAVP challenge after water deprivation is the key test: urine concentrates by >50% = central DI; <10% increase = nephrogenic DI.

Lithium is the most common drug cause of nephrogenic DI.

DI vs. primary polydipsia: water deprivation test — in primary polydipsia, urine concentrates normally; in DI, it stays dilute.

Pituitary dwarfism

Patient will present as → a 3-year-old male who is brought to your office by his mother, who is concerned that he is not growing appropriately. Physical examination is notable for frontal bossing and shortened upper and lower extremities. His axial skeleton appears normal. He is at the 4th percentile for height and 95th percentile for head circumference. He demonstrates normal intelligence and is able to speak in three-word sentences. He first sat up without support at twelve months and started walking at 24 months. Labs reveal decreased GH and decreased IGF 1.

Pituitary dwarfism, or growth hormone deficiency, is a condition in which the pituitary gland does not make enough growth hormone. This results in a child's slow growth pattern and unusually small stature (below average height)

Growth hormone (GH) deficiency can occur in isolation or in association with generalized hypopituitarism. Causes include congenital (including genetic) disorders and a number of acquired disorders of the hypothalamus and/or pituitary

  • Presentation: Short stature/limbs, prominent brow, midfacial hypoplasia
  • The primary manifestations of growth hormone deficiency in infancy are hypoglycemia and micropenis
  • Serial measurements > 2.5 deviations below the normal mean should prompt growth hormone evaluation

DX: Diagnosis can be confirmed by low levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3

  • Labs: ↓ GH, ↓ IGF1
  • BONE AGE: The primary symptom of pituitary dwarfism is lack of height. Therefore, a change in the individual's growth habits will help lead to a diagnosis.
    • X-ray the child's hand to determine the child's bone age by comparing this to the child's actual chronological age
  • CT or MRI of the brain to evaluate for cause

Treatment:

If dwarfism is due to decreased human growth hormone and not due to a primary skeletal disorder, the child can be treated with human growth hormone treatments to try and stimulate normal growth.

Surgery may be necessary to remove a pituitary adenoma if that is the cause of dwarfism

Ethan Crough, male dwarf

This is an image of Ethan Crough, a man with dwarfism who lives in Columbus, Indiana.

Pituitary adenoma and Pituitary neoplastic disease

Patient will present as → a 31-year-old woman who complains of irregular, infrequent menstrual periods. On further questioning, she complains of headaches, fatigue, and breast discharge. She takes ibuprofen only occasionally. The serum prolactin level is 380 μg per L. (prolactinoma)

The most common tumors are microadenomas that are functional (hypersecretion of pituitary hormones), nonfunctional or compressive

  • Microadenomas are less than 1 cm in diameter, whereas adenomas that are 1 cm or more are commonly referred to as macroadenomas
    • Microadenoma < 10 mm
    • Macroadenoma > 10 mm

Diagnosis:

  • MRI is the study of choice to look for sellar lesions/tumors
  • Endocrine studies: Prolactin, GH, ACTH, TSH, FSH, LH

1810 Major Pituitary Hormones

Classification of Pituitary Adenomas
Tumor Type Secretory Product(s) Relative Frequency (%)
1. Prolactinoma (Galactorrhea)

  • Most common
  • Secrete prolactin
  • Presentation: Galactorrhea, infertility, amenorrhea
  • Treatment: Bromocriptine
↑ Prolactin 50%
2. Somatotroph Adenoma (Acromegaly)

  • Secrete GH
  • Presentation: Acromegaly
  • Treatment: Resection is the first line
↑ Growth Hormone/Prolactin 10%
3. Corticotroph Adenoma (Cushing's Syndrome)

↑ ACTH 5%
4. Thyrotroph Adenoma (Hyperthyroidism)

↑ TSH 1%
5. Non-Secreting Adenoma

  • Null Cell - No secretion
(α) alpha -subunit 34%
Syndrome of Inappropriate Antidiuretic Hormone (SIADH)

Patient will present as → a 68-year-old man with small cell lung cancer presents with confusion, nausea, and vomiting. Labs show serum sodium 118 mEq/L, serum osmolality 244 mOsm/kg, urine osmolality 620 mOsm/kg, and urine sodium 42 mEq/L. He is euvolemic on exam (no edema, no orthostatic hypotension, mucous membranes moist). He is not on diuretics. His creatinine, TSH, and cortisol are normal.

Syndrome of Inappropriate Antidiuretic Hormone (SIADH) secretion is a clinical disorder characterized by the autonomous, excessive release of ADH [Antidiuretic Hormone], leading to impaired renal water excretion that results in euvolemic hyponatremia and inappropriately concentrated urine (Urine Osmolality >100 mOsm/kg) despite low serum osmolality

  • SIADH: inappropriately elevated ADH → excess free water retention → dilutional hyponatremia + concentrated urine (urine osmolality inappropriately high relative to low serum osmolality)
  • Key diagnostic features (euvolemic hyponatremia):
    • Low serum sodium (<135 mEq/L)
    • Low serum osmolality (<275 mOsm/kg)
    • Urine osmolality >100 mOsm/kg (inappropriately concentrated)
    • Urine sodium >20–40 mEq/L (renal sodium excretion continues)
    • Euvolemic (no edema, no orthostatic hypotension)
    • Normal thyroid and adrenal function (hypothyroidism and adrenal insufficiency must be excluded)
  • Causes (SIADH causes hyponatremia in specific settings):
    • Pulmonary: small cell lung cancer (most common malignancy causing SIADH — ectopic ADH), pneumonia, TB, abscess, pulmonary embolism, ARDS, positive pressure ventilation
    • CNS: trauma, stroke, SAH, meningitis, encephalitis, brain tumor, hydrocephalus, Guillain-Barré
    • Medications: SSRIs (most common drug cause), SNRIs, carbamazepine, cyclophosphamide, chlorpropamide, NSAIDs, MDMA (ecstasy), vincristine, oxcarbazepine, desmopressin, opioids
    • Hypothyroidism and adrenal insufficiency: must be excluded before diagnosing SIADH (both cause euvolemic hyponatremia by similar mechanism)

Signs and Symptoms

  • Mild-moderate hyponatremia (Na 120–134): nausea, headache, malaise, fatigue, cognitive impairment
  • Severe hyponatremia (Na <120 or rapid decline): confusion, seizures, coma, cerebral edema → herniation (life-threatening)
  • Euvolemic status: normal skin turgor, mucous membranes, blood pressure, heart rate; no edema; no orthostatic changes

DX: SIADH is a diagnosis of exclusion

  • Euvolemic hyponatremia: low serum Na + low serum osmolality + urine osmolality >100 mOsm/kg + urine Na >20 mEq/L
  • Exclude: hypothyroidism (TSH), adrenal insufficiency (cortisol/ACTH stim), diuretic use, hyperglycemia (pseudohyponatremia), renal disease, liver cirrhosis, heart failure (hypervolemic)
  • Workup for cause: CXR/CT chest (lung cancer, pneumonia), brain MRI (CNS cause), medication review

TX: Fluid restriction is first-line!

  • Mild, asymptomatic SIADH (Na >125): fluid restriction (500–1,000 mL/day) — first-line; treat underlying cause
  • Moderate, symptomatic (Na 120–125 or mild symptoms): fluid restriction + salt tablets or oral urea; demeclocycline (blocks ADH action in collecting duct — used for chronic SIADH from malignancy)
  • Severe, symptomatic (Na <120, seizures, coma): 3% hypertonic saline IV; target: raise Na by 1–2 mEq/L/hr until symptoms resolve; do NOT exceed 8–10 mEq/L in 24 hours (risk of osmotic demyelination syndrome — ODS)
  • Vaptans (vasopressin receptor antagonists): tolvaptan (Samsca), conivaptan (Vaprisol IV); block V2 receptor → aquaresis (free water loss); used for chronic SIADH unresponsive to fluid restriction; avoid in liver disease (tolvaptan hepatotoxicity); do not use in hypovolemic hyponatremia
  • Osmotic demyelination syndrome (ODS) / central pontine myelinolysis: occurs with too-rapid correction of hyponatremia (>10–12 mEq/L per 24 hrs) → irreversible demyelination of pontine neurons → quadriplegia, dysarthria, dysphagia, locked-in syndrome; highest risk: alcoholism, malnutrition, liver disease, hypokalemia

PEARLS:

  • SIADH = euvolemic hyponatremia + low serum osmolality + urine osmolality >100 + urine Na >20.
  • Small cell lung cancer is the classic malignancy cause.
  • SSRIs are the most common drug cause.
  • Fluid restriction is first-line.
  • For severe/symptomatic: 3% hypertonic saline — but NEVER correct sodium faster than 8–10 mEq/L per 24 hours or you risk osmotic demyelination syndrome (central pontine myelinolysis) → permanent neurologic catastrophe.
  • Vaptans cause free water excretion (aquaresis) without electrolyte loss.
Picmonic
The posterior pituitary

posterior-pituitary_5682_1476761567

The posterior pituitary is an endocrine gland primarily composed of the nerve terminals of axons extending from the hypothalamus. It is important in the neuroendocrine reflex, which occurs when sensory neurons are stimulated resulting in action potential in hypothalamic cells and exocytosis of hormones from the posterior pituitary. Vasopressin is one of the hormones released from the posterior pituitary. Vasopressin is synthesized in the hypothalamus but stored in the posterior pituitary and released in response to synaptic input from osmoreceptors that detect increased osmolality of blood plasma. This hormone affects the kidney into retaining more water and also can constrict blood vessels. The second hormone released from the posterior pituitary is Oxytocin. It is released via a neuroendocrine reflex in response to stimulation of the nipples during breastfeeding that causes the mammary glands to contract and release milk. Stimulation of the nipples causes action potential generation in the oxytocin cells of the hypothalamus, which travels down to the nerve endings in the posterior pituitary and results in the exocytosis of Oxytocin. It also causes uterine smooth muscle contraction during the second and third stages of labor.

Play Video + Quiz

Anterior pituitary

anterior-pituitary_5186_1477332872

The anterior pituitary is an endocrine gland that releases a variety of hormones in response to stimuli from the hypothalamus and other sources. ACTH, adrenocorticotropic hormone, stimulates the adrenal glands into releasing cortisol. FSH and LH both stimulate the gonads (ovaries and testes). FSH (follicle-stimulating hormone) regulates reproductive processes, sexual maturation, development, and growth. LH stimulates the ovaries and testes into producing estrogen and progesterone, and testosterone respectively. Thyroid-stimulating hormone (TSH) stimulates the thyroid gland into producing thyroxine (T4) and triiodothyronine (T3), both of which stimulate metabolism in most tissues. Prolactin is a peptide hormone that stimulates milk production from the mammary glands and can affect levels of sex hormones. The other hormones released, but not shown here, are endorphins, which are released in response to exercise, pain, and excitement and cause a feeling of analgesia (well-being). Finally, growth hormone stimulates cell reproduction, development, and growth.

Play Video + Quiz

Hypoparathyroidism (Lecture) (Prev Lesson)
(Next Lesson) Acromegaly/gigantism (Growth Hormone) Lecture
Back to PANCE Blueprint Endocrinology (6%)

Have you tried the NEW Smarty PANCE QBANK? It's FREE with EVERY membership purchase 😀!

X